CZCecilia Zivelonghi

Cecilia Zivelonghi

*This is an algorithmically generated author record based on publicly available information.

Cecilia Zivelonghi has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cerebral air embolism: A hidden cause of acute ischemic stroke

    by Cecilia Zivelonghi, Carlo Alberto De Pasqual, Mauro Plebani, Manuel Cappellari

    A 46‐year‐old man presented to the Emergency Department because of food bolus impaction after an emergent esophagogastroduodenoscopy (EGD). Three hours after the procedure, awakening from general anesthesia, he complained drowsiness and left‐sided weakness. Brain CT scan was unremarkable, while CT angiography performed later revealed signs of pneumomediastinum likely from an esophageal laceration. Thorough cardiological, hematological, and rheumatological investigations during hospital stay proved unremarkable. Cerebral air embolism (CAE) has been reported as a potential complication of endoscopic procedures, but the precise mechanism is still unknown.


  • Septin‐5 and ‐7‐IgGs: Neurologic, Serologic, and Pathophysiologic Characteristics

    by Shannon R. Hinson, Josephe A. Honorat, Ethan M. Grund, Benjamin D. Clarkson, Ramona Miske, Madeleine Scharf, Cecilia Zivelonghi, Muhammad Taher Al‐Lozi, Robert C. Bucelli, Adrian Budhram, et al.

    Background and Objectives: We sought to determine clinical significance of neuronal septin autoimmunity and evaluate for potential IgG effects.Methods: Septin‐IgGs were detected by indirect immunofluorescence assays (IFAs; mouse tissue and cell based) or Western blot. IgG binding to (and internalization of) extracellular septin epitopes were evaluated for by live rat hippocampal neuron assay. The impact of purified patient IgGs on murine cortical neuron function was determined by recording extracellular field potentials in a multielectrode array platform.Results: Septin‐IgGs were identified in 23 patients. All 8 patients with septin‐5‐IgG detected had cerebellar ataxia, and 7 had prominent eye movement disorders. One of 2 patients with co‐existing septin‐7‐IgG had additional psychiatric phenotype (apathy, emotional blunting, and poor insight). Fifteen patients had septin‐7 autoimmunity, without septin‐5‐IgG detected. Disorders included encephalopathy (11; 2 patients with accompanying myelopathy, and 2 were relapsing), myelopathy (3), and episodic ataxia (1). Psychiatric symptoms (≥1 of agitation, apathy, catatonia, disorganized thinking, and paranoia) were prominent in 6 of 11 patients with encephalopathic symptoms. Eight of 10 patients with data available (from 23 total) improved after immunotherapy, and a further 2 patients improved spontaneously. Staining of plasma membranes of live hippocampal neurons produced by patient IgGs (subclasses 1 and 2) colocalized with pre‐ and post‐synaptic markers. Decreased spiking and bursting behavior in mixed cultures of murine glutamatergic and GABAergic cortical neurons produced by patient IgGs were attributable to neither antigenic crosslinking and internalization nor complement activation.Interpretation: Septin‐IgGs are predictive of distinct treatment‐responsive autoimmune central nervous system (CNS) disorders. Live neuron binding and induced electrophysiologic effects by patient IgGs may support septin‐specific pathophysiology. ANN NEUROL 2022;92:1090–1101


  • Open Access

    Benefit from successful recanalization in an Italian cohort of stroke patients receiving endovascular treatments according to the DIRECT-MT trial criteria

    by Manuel Cappellari, Valentina Saia, Giovanni Pracucci, Fabrizio Sallustio, Andrea Zini, Mauro Bergui, Cecilia Zivelonghi, Salvatore Mangiafico, Danilo Toni

    Introduction: To identify predictors of 3-month mRS score and to estimate the benefit from successful recanalization across baseline subgroups of Italian Registry of Endovascular Treatment in Acute Stroke (IRETAS) cohort of stroke patients receiving endovascular treatments according to the DIRECT-MT criteria. Methods: Using a model of propensity score matching, we retrospectively identified an IRETAS cohort of 137 patients receiving bridging who were matched with 137 patients receiving MT alone according to the DIRECT-MT criteria. Results: Differences were found between DIRECT-MT and IRETAS cohorts for 3-month mRS score 0 to 1 (23.5% vs. 33.1%) and 0 to 2 (36.7% vs. 47.1%), successful (82% vs. 76.7%) and complete recanalization (32.3% vs. 58.8%). Among unfavorable predictors for 3-month mRS shift, diabetes mellitus (18.9% vs. 13.9%) and asymptomatic intracerebral hemorhage (ICH) (34.8% vs. 25.5%) were more frequent in the DIRECT-MT, whereas age ≥80 years (23.7% vs. 15.3%) and pre-stroke mRS score >0 (16.1% vs. 7.8%) were more frequent in the IRETAS. The direction of effect on the 3-month mRS shift (6 to 0) favored successful recanalization across all strata. Greatest benefit from successful recanalization was observed in patients with most severe strokes (NIHSS ≥20, OR:4.002; 16–19, OR:3.292; 2–5, OR:2.470) and most proximal occlusion site (intra-cranial ICA, OR:4.092; M1-MCA, OR:3.705; M2-MCA, OR:2.001), in younger patients (18–59 years, OR:3.677; 60–79, OR:3.267; ≥80, OR:1.993), and in patients who started the treatment earlier (onset-to-groin time ≤205 min, OR:4.361; onset-to-groin time >205, OR:2.326). Conclusions: The benefit from successful recanalization for 3-month mRS shift in the direction of favorable outcome was different across baseline subgroups.

  • Open Access

    Peripheral neuropathies during the COVID-19 pandemic: is there a relation?

    by Milena Trentinaglia, Giuseppe Lippi, Gian Luca Salvagno, Marianna G. Rispoli, Maria Vittoria De Angelis, Francesca Castellani, Daniela Alberti, Giorgia T. Maniscalco, Francesca Rossi, Mara Turri, et al.


  • Open Access

    Nervous system: subclinical target of SARS-CoV-2 infection

    by Sara Mariotto, Alessia Savoldi, Katia Donadello, Serena Zanzoni, Silvia Bozzetti, Sara Carta, Cecilia Zivelonghi, Daniela Alberti, Francesco Piraino, Pietro Minuz, et al.

    Neurofilament light chain (NfL) is the most abundant and soluble protein of the neuronal cytoskeleton and is released during axonal injury. An increase of cerebrospinal fluid (CSF) and serum levels of NfL has been demonstrated in patients with several inflammatory and degenerative neurological disorders of the nervous system, in correlation with clinical and radiological activity.1 Several clinical reports showed that patients with COVID-19 suffer from neurological symptoms including non-specific manifestations as headache, hyposmia, dysgeusia and altered consciousness.2 To date, the pathogenesis of the aforementioned symptoms and the role of inflammatory factors in the context of this severe systemic condition have not been elucidated. Different possible mechanisms of neuronal damage have been hypothesised, including direct viral nervous system invasion through hematogenous dissemination or neuronal retrograde dissemination and indirect injury mediated by inflammatory processes due to the cytokine storm.2 The aim of this study was to explore the nervous system involvement in patients with COVID-19 by evaluating the presence of neurological symptoms and measuring serum NfL levels as biomarker of axonal damage.


  • Vertebral Artery Fenestration Mimicking Acute Dissection

    by Cecilia Zivelonghi, Andrea Emiliani, Nicola Micheletti, Stefano Tamburin